NCT01053728View on ClinicalTrials.gov

Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

May 31, 2010

Study Completion Date

November 30, 2010

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

SAR161271

"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"

DRUG

Insulin glargine HOE901

"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Berlin

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT01053728 - Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM) | Biotech Hunter | Biotech Hunter